Picture of Eli Lilly and logo

LLY — Eli Lilly and News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Brief: EMA's CHMP Recommends Extensions Of Indication For Bexsero & Talzenna

BRIEF-EMA's CHMP Recommends Extensions Of Indication For Bexsero & Talzenna

- EMA's CHMP:

  • EMA'S CHMP: RECOMMENDED EXTENDING USE OF GAZYVARO (OBINUTUZUMAB) TO TREAT ADULTS WITH MODERATE-TO-SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS

  • EMA'S CHMP: RECOMMENDS GRANTING MARKETING AUTHORISATION FOR BAXFENDY

  • EMA'S CHMP: RECOMMENDED EXTENSIONS OF INDICATION FOR BEXSERO, COSENTYX, DOVATO, ENFLONSIA, STEGLATRO, SUNLENCA, TALZENNA, TIVICAY, WELIREG

  • EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR TALZENNA

  • EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR STEGLATRO

  • EMA'S CHMP: ADOPTED DHPC ABOUT POTENTIAL EFFECT OF MOUNJARO (TIRZEPATIDE) ON RELIABILITY OF ORAL CONTRACEPTIVES

  • EMA'S CHMP: DHPC REMINDS HEALTHCARE PROFESSIONALS THAT CONTRACEPTION IS RECOMMENDED FOR WOMEN WHO CAN BECOME PREGNANT & USING MOUNJARO


((Reuters.Briefs@thomsonreuters.com;))

Recent news on Eli Lilly and

See all news